Related Experiment Videos
2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer
L R Qadan1, C M Perez-Stable, C Anderson
1Geriatric Research, Education, and Clinical Center and Research Service, VA Medical Center, Miami, Florida 33125, USA.
Abstract:
Few therapeutic treatment options are available for patients suffering from metastatic androgen-independent prostate cancer. We investigated the ability of the estrogen metabolite 2-methoxyestradiol to inhibit the proliferation of a variety of human prostate cancer cell lines in vitro and to inhibit the growth of androgen-independent prostate cancer in a transgenic mouse model in vivo. Our results showed that 2-methoxyestradiol is a powerful growth inhibitor of LNCaP, DU 145, PC-3, and ALVA-31 prostate cancer cells. Cell flow cytometry of 2-methoxyestradiol-treated DU 145 cells showed a marked accumulation of cells in the G2/M phase of the cell cycle and an increase in the sub-G1 fraction (apoptotic). In addition, staining for annexin V, changes in nuclear morphology, and inhibition of caspase activity support a role for apoptosis. More importantly, we showed that 2-methoxyestradiol inhibits prostate tumor progression in the Ggamma/T-15 transgenic mouse model of androgen-independent prostate cancer without toxic side effects. These results in cell culture and an animal model support investigations into the clinical use of 2-methoxyestradiol in patients with androgen-independent prostate cancer.
Insights
The estrogen metabolite 2-methoxyestradiol effectively inhibits prostate cancer cell growth and tumor progression in mice. This compound shows promise as a new therapeutic for androgen-independent prostate cancer without causing toxic side effects.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Metastatic androgen-independent prostate cancer has limited therapeutic options.
- Estrogen metabolites are being explored for their anti-cancer properties.
Purpose of the Study:
- To evaluate 2-methoxyestradiol's efficacy in inhibiting prostate cancer cell proliferation in vitro.
- To assess 2-methoxyestradiol's effect on androgen-independent prostate cancer growth in a transgenic mouse model in vivo.
Main Methods:
- In vitro studies using human prostate cancer cell lines (LNCaP, DU 145, PC-3, ALVA-31).
- Cell cycle analysis (flow cytometry) and apoptosis assays (annexin V staining, nuclear morphology, caspase activity) on treated cells.
- In vivo studies using the Ggamma/T-15 transgenic mouse model of androgen-independent prostate cancer.
Main Results:
- 2-methoxyestradiol demonstrated potent growth inhibition across multiple prostate cancer cell lines.
- Treatment induced G2/M cell cycle arrest and apoptosis in DU 145 cells.
- Significant inhibition of prostate tumor progression was observed in the mouse model without observable toxic side effects.
Conclusions:
- 2-methoxyestradiol exhibits significant anti-proliferative and pro-apoptotic effects on prostate cancer cells.
- The compound effectively inhibits tumor progression in an animal model of androgen-independent prostate cancer.
- These findings support further clinical investigation of 2-methoxyestradiol for treating advanced prostate cancer.